1. 1) Tullu MS. Oseltamivir. J. Postgrad. Med., 55, 225–230 (2009).
2. 2) Kitahara K, Nakamura Y, Tsuneoka Y, Adachi-Akahane S, Tanaka H, Yamazaki H, Takahara A, Yamazaki J, Ikeda T, Sugiyama A. Cardiohemodynamic and electrophysiological effects of anti-influenza drug oseltamivir in vivo and in vitro. Cardiovasc. Toxicol., (2013), in press.
3. 3) Takahara A, Takeda K, Tsuneoka Y, Hagiwara M, Namekata I, Tanaka H. Electrophysiological effects of the class Ic antiarrhythmic drug pilsicainide on the guinea-pig pulmonary vein myocardium. J. Pharmacol. Sci., 118, 506–511 (2012).
4. 4) Takahara A, Takeda K, Hagiwara M, Tanaka H. Electrophysiological effects of the antiarrhythmic drug bepridil on the guinea-pig pulmonary vein myocardium. Biol. Pharm. Bull., 36, 311–315 (2013).
5. 5) Chugai Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. Non-clinical studies conducted by order of the basic working group and results of voluntary examination and analysis (No. 2). P47-57, December 10, 2007. The 4th working group for basic research and examination of oseltamivir phosphate. (in Japanese): ‹http://www.mhlw.go.jp/shingi/2007/12/s1210-6.html›, cited 12 July, 2013.